SCYNEXIS, Inc. fell 14.1% on Thursday, November 5, 2026, on 133,700 shares. Headlines around the move:
SCYNEXIS, Inc. (SCYX:NASDAQ) closed at $3.52 on November 10, 2026, up 0.57% on the day. The stock trades 61.4% below its 52-week high of $9.12 and 7.3% above its 52-week low of $3.28. Over the past year, it lost 26.8%. SCYNEXIS, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 10, 2025, SCYX closed higher on 110 days (44%). Its best day was July 31, 2026 (+29.76%) and its worst was November 5, 2026 (-14.06%). The stock moved 10% or more in a single session 10 times.
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Find more stocks like SCYX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.